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a b s t r a c t
Pancreas disease (PD) in salmonid ﬁsh is caused by an infection with Salmonid alphavirus (SAV) and
remains as one of the major health problems in the European ﬁsh farming industry. Sequence studies
have revealed a genetic diversity among viral strains. A subtype of SAV (SAV3) is causing an epizootic in
farmed salmonids in Norway. Here we evaluate efﬁcacy and safety of an inactivated virus vaccine based
on ALV405, a strain of SAV3 that was isolated from Norwegian salmon. The vaccine provided an average
relative percent survival (RPS) of 98.5 in an intraperitoneal challenge model, and induced nearly total
protection against PD in a cohabitant challenge model. It provided signiﬁcant protection against SAV-almo salar
ish vaccine
quaculture
inducedmortality also in a ﬁeld trial under industrial conditions. Local reactions seen asmelanization and
adhesions in the visceral cavity were less severe than those induced by two commercial vaccines. Finally,
we demonstrated that the protection is not impaired when the ALV405 antigen is combined with other
viral or bacterial antigens in a polyvalent vaccine. The results conﬁrm that efﬁcient and safe protection
against SAV infection and development of PD is possible using an inactivated virus vaccine, both alone
polyvand as a component in a
. Introduction
Pancreas disease (PD) in Atlantic salmon (Salmo salar) and rain-
ow trout (Oncorhynchus mykiss) is caused by strains of the Salmon
ancreas Disease virus (family Togaviridae), commonly named
almonid alphavirus (SAV) [1,2]. The disease has been reported
rom farmed ﬁsh in most European countries that farm salmonids
3]. InNorway, it is regardedasoneof themost costlydiseases to the
ndustry. The economical loss from PD is a result of several factors
ncluding mortality of infected ﬁsh, reduced growth of survivors
nd reduced quality of the ﬁllet [4]. PD is also a welfare problem,
ince large parts of the ﬁsh that are put to sea in Norway become
nfected.
The genome of SAV is a capped and polyadenylated single-
tranded RNA molecule with two open reading frames, encoding
on-structural and structural polyproteins [2]. A neutralizing epi-
ope has been mapped to the E2 protein, which functions in
eceptor-binding in other alphaviruses [5]. Phylogenetic analyses
f thepartial coding regionof E2have suggested four distinct clades
o exist. These clades have been divided into six genetic subtypes,
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SAV1-6 [6]. The phenotypic consequences of these genetic differ-
ences are not known.
The phylogeographic structure of SAV suggests that several
independent epizootics of PD are currently occurring in European
aquaculture. Most strains from Norway belong to subtype 3 and
constitute a distinct epizootic compared to outbreaks in other parts
of Europe where subtypes 1, 2, 4–6 have been reported [6–9].
Although wild reservoirs and transmission patterns of SAV are
largely unknown, viral RNA has been detected in the water during
viraemia, and cohabitant ﬁsh are readily infected [1,10]. It therefore
appears likely that the virus transmits by water contact once it has
entered a farm. Following infection, viral RNA can be detected in
most organs of the ﬁsh, at least during viraemia. Heart tissues con-
tain the highest levels of viral RNA [3,11]. Tissue lesions have been
reported primarily from exocrine pancreas, the heart and skeletal
muscle. Lesions in brain and kidney are also found sporadically [3].
The infection may lead to mortality and highly variable mortality
rates have been reported from ﬁeld outbreaks [12,13]. The reason
for the variations in mortality rates is not yet understood, but is
likely to be a combination of virulence differences among strains
of SAV, co-infections with other pathogens and environmental fac-
tors.
It is possible to obtain immunity against SAVand several vaccine
concepts have been explored [14–17]. An inactivated whole-virus
vaccine based on the Irish type-strain of SAV, F93-125 (subtype 1),
cine 3
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as been commercially available since 2002. Although the industry
as vaccinated most ﬁsh that are put to sea in the region of Norway
here SAV3 is regarded to be enzootic, PD has remained as one of
he major disease problems [13]. We  have developed an inactivated
accine based on a strain of SAV subtype 3 – ALV405. Here we eval-
ate the efﬁcacy and safety of this vaccine, and demonstrate that it
ould be an attractive new tool for controlling SAV epizootics.
.  Materials and methods
.1.  Vaccines
All  vaccines used in this study were water-in-oil formulations
here the water phase (containing antigens) was dispersed into
 mineral oil phase (continuous phase containing emulsiﬁers and
tabilizers). Emulsiﬁcation of the antigen with adjuvant was done
sing a homogenizer with a standard emulsiﬁcation stator/rotor
onnected to an emulsion screen. The formalin-inactivated ALV405
ntigen was formulated into a monovalent vaccine (ALPHA JECT
icro®1 PD, PHARMAQ AS, Norway), or into several polyvalent
accines where six components that are heterologous to SAV also
ere present at a ﬁxed concentration, and where the concentration
f ALV405 varied as described below. The six additional compo-
ents were identical to those found in the commercial injectable
il-based vaccines ALPHA JECT micro®6 (0.05 ml/ﬁsh dose) and
LPHA JECT®6-2 (0.1 ml/ﬁsh dose) (PHARMAQ AS, Norway). These
accines contain ﬁve bacterial (Aeromonas salmonicida, Listonella
nguillarum serotypes 1 and 2, Vibrio salmonicida, Moritella viscosa)
nd one viral antigen (infectious pancreatic necrosis virus, IPNV).
 vaccine was also formulated without any antigen to serve as an
djuvant placebo control. A commercially available vaccine against
AV (Norvax®Compact PD, MSD  Animal Health), was used as ref-
rence to the new ALV405-based vaccine in some efﬁcacy studies.
ommercial vaccines were always used within the deﬁned expiry
ate and according to manufacturer recommendations, except that
hey in lab trials were removed from the original container and
ransferred by standard sterile techniques to sterile 50 ml  tubes
hat were blinded to the operator.
.2. Genetic characterization of virus strains
Three different SAV strains were used either as vaccine antigen
ALV405) or as challenge strains (ALV407 or ALV413). These strains
riginated from Atlantic salmon from Norway diagnosed with Pan-
reas disease. The genotype of these isolates was determined by
equencing of a 1.3 kB cDNA fragment covering the partial open
eading frame encoding structural proteins as previously described
7]. All isolates were conﬁrmed to share >99.8% nucleotide identity
o the previously reported SAV3 sequence DQ122130.
.3. Fish vaccination in laboratory trials
Fish handling, including vaccination, sampling, mortality regis-
ration, sample processing and sample analyses was  done blinded
o the operator. Unvaccinated Atlantic salmon (S. salar L.) were
edated using Metacaine (MS222, PHARMAQ Ltd, UK), tagged for
dentiﬁcation and vaccinated by intraperitoneal injection. Vaccina-
ion was always performed according to the recommendations of
he manufacturer and temperature was set to 12 ◦C, unless other-
ise stated. Tanks were monitored daily for clinical signs of disease
r mortalities..4. Challenge in laboratory trials
In efﬁcacy trials, ﬁsh were challenged with a SAV-strain het-
rologous to the vaccine strain. Fish were starved 24 h prior to0 (2012) 5688– 5694 5689
challenge.  On the day of challenge, the ﬁsh were anaesthetized with
Metacaine and i.p. injected with 0.1 ml  of the challenge strain. No
mortality or abnormal behaviour was observed associated with the
challenge procedure.
2.5.  Intraperitoneal and cohabitant challenge – efﬁcacy studies
Atlantic  salmon (n = 80 per group) were tagged by ink tat-
tooing or shortening of adipose ﬁns or maxillae, and vaccinated
(mean weight at vaccination: 37.5 g) with one of four vaccines:
the monovalent ALV405-based vaccine (0.05 ml/ﬁsh), a commercial
monovalent SAV vaccine (0.1 ml/ﬁsh), a placebo adjuvant vaccine
(0.1 ml/ﬁsh) or PBS (0.1 ml/ﬁsh). After a six weeks smoltiﬁcation
period, the ﬁsh were distributed to duplicate tanks with seawa-
ter. The ﬁsh that were to be evaluated in the i.p. injection model,
and that served as shedders for the ﬁsh in the cohabitation model,
were then challenged with the isolate ALV413 at a ﬁnal dose of
1.15 ×108 TCID50/ﬁsh.
Samples  from heart, pancreas and skeletal muscle were taken
for histological analysis from all cohabitant groups 3–5 weeks post
challenge (n = 10 per tank/20 per group, per time point, unless
otherwise stated). Heart-tissues were also stored on RNA-later
(Ambion) and used for RNA extraction and PCR analyses. Sera were
collected from the caudal vein for evaluation of viraemia by iso-
lation of infectious virus in Chum salmon heart (CHH) cells using
previously described techniques [18,19]. Samples were also taken
from surviving ﬁsh in the i.p. challenged groups four weeks p.i.
(n = 5 per tank/10 per group, except for in the PBS placebo group
where n = 4 and 2 from the two tanks due to few survivors).
2.6. Histology
Tissues were ﬁxed in 10% phosphate-buffered formalin for a
minimum of 48 h prior to being submitted blinded to the Norwe-
gian Veterinary Institute, Oslo, Norway for embedment in parafﬁn
wax, sectioning at 4–5 m and staining with hematoxylin and eosin
according to their standard procedure. Blinded slides were scored
for lesion severity using a visual analogous scale as previously
described [17] (Supplementary Table 1).
2.7. RNA extraction, reverse transcriptase Real-Time PCR and
quantiﬁcation of RNA
Heart  samples were collected aseptically without penetrat-
ing the peritoneal cavity, stored on RNAlater and submitted
to an accredited commercial laboratory for RNA extraction and
Real-Time PCR analyses (PatoGen Analyse AS, Ålesund, Norway).
The returned results were treated as positive/negative, or semi-
quantitative. In the latter case, raw Ct-values that were obtained
with a previously described Taqman assay targeting the coding
sequence of SAV nsP1 [20] were normalized against the Ct-values
from an assay targeting the mRNA of cellular elongation factor 1a
[21] using the Q-gen software [22]. PCR efﬁciencies for the two
assays were provided by PatoGen Analyse AS for inclusion in the
analysis (slopes = −3.25 for SAV and −3.41 for ElA). Normalized Ct-
values were divided by the lowest value in the groups compared
and Log2 transformed for presentation.
2.8. Field trial
The  trial included two cages of Atlantic salmon (Cage 1:
n = 109 203, cage 2: n = 126 254), held under industrial conditions
at a commercial seawater ﬁsh farm in Western Norway. All the
ﬁsh were of the same strain and origin and were vaccinated in
the freshwater stage (January 11th–February 3rd, 2011) with the
commercial multi-component vaccine ALPHA JECT micro®6, that
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oes not contain any SAV antigens. In addition to this vaccine,
ll ﬁsh were vaccinated with either the commercial monovalent
accine against SAV or the monovalent ALV405-based SAV vac-
ine. Vaccines were only injected once in each ﬁsh, with a dose
f 0.05 ml  for ALPHA JECT micro®6 and the ALV405-based vac-
ine, and 0.1 ml  for the commercial SAV vaccine. All vaccinations
ere done automatically by Lumic vaccination machines (Lumic AS,
orway), according to recommendations from the manufacturers.
his implies that ﬁsh were vaccinated with the commercial SAV
accine (December 2nd–14th, 2010) approximately seven weeks
rior to injection of ALPHA JECT micro®6, while the ALV405-based
accine was injected simultaneously with this vaccine. Fish vacci-
ated with either the commercial SAV vaccine or the ALV405-based
accine, were held separately until transfer to the sea cages, where
hey were mixed to avoid cage effects. The proportion of ﬁsh vacci-
ated with the ALV405-based vaccine was 18.3% and 16.1% in cages
 and 2, respectively, while the remaining ﬁsh were vaccinated
ith the commercial SAV-vaccine. The groups were identiﬁed by
emoval of the adipose ﬁn for ﬁsh vaccinated with the ALV405-
ased vaccine. Mortalities were recorded daily, and ﬁsh health was
onitored by an external ﬁsh health service. Ofﬁcial diagnosis of
D was made by the Norwegian Veterinary institute according to
heir criteria. Mortalities in the study-population were recorded
aily until October 5th, 2011.
.9. Safety study
Atlantic  salmon (mean weight: 35.5 g) were vaccinated with
he monovalent ALV405-based vaccine (0.05 ml  dose) or the com-
ercial vaccines ALPHA JECT micro®6 (0.05 ml  dose) or ALPHA
ECT®6-2 (0.1 ml  dose) (n = 35 in each group). Fish were kept at
7 ◦C water temperature throughout the experiment. Adhesions
nd melanization of the viscera were recorded 6 and 12 weeks
ost vaccination (n = 15 per group, per sampling) using a modiﬁed
peilberg scale [23].
.10.  Dose-response and efﬁcacy of polyvalent vaccines
The efﬁcacy of polyvalent ALV405-based vaccines with different
ntigenic dose were tested in a intraperitoneal challenge model.
tlantic salmon were tagged, vaccinated and allocated to duplicate
anks according to Table 1. The challenge was done as described
bove, except that no cohabitant groups were included, and the
hallenge isolate ALV407 was used. Efﬁcacy was measured by rel-
tive percent survival.
.11.  Statistical analyses
The  softwares GraphPad Prism 5 and InStat 3 were used for all
tatistical analyses. Relative percent survival (RPS) was  calculated
y the following formula: (1 − (% mortality in test group/% mortality
n control group)) × 100.
.  Results
.1. The ALV405-based vaccine protects against SAV-induced
ortality and disease following intraperitoneal challenge
The  challenge isolate ALV413 caused an accumulated mor-
ality of 87.5% in both parallel tanks in the i.p. challenged ﬁsh
hat had received the PBS placebo vaccine (Fig. 1A). The inacti-
ated ALV405-based vaccine provided a highly efﬁcient protection
gainst mortality with a relative percent survival of 100 and 97
n the two parallel tanks (average RPS = 98.5). It performed signiﬁ-
antly better than the commercial SAV vaccine, which gave an RPS
f 79 and 51 (Average RPS = 65, p < 0.0001 using Fisher’s exact test).0 (2012) 5688– 5694
The  adjuvant placebo vaccine also provided a signiﬁcant effect com-
pared to the PBS placebo group, with an RPS of 45 and 20 (average
RPS = 32.5, p < 0.0001 using Fisher’s exact test).
Virus  RNA levels in hearts were measured four weeks p.i. in ﬁve
surviving ﬁsh per tank per group. This demonstrated that viral RNA
was  efﬁciently produced in all groups except the groups vaccinated
with the inactivated ALV405-based vaccine (Fig. 1B). In these latter
groups, ﬁsh seemed to be completely protected against replication
of the challenge strain. Viral RNA production in survivors did not
differ in this organ between the placebo-vaccinated groups and
the groups vaccinated with the commercial SAV vaccine. Similarly,
histopathological changes developed in heart, pancreas and skele-
tal muscle of all groups except in the groups vaccinated with the
ALV405-based vaccine (Fig. 1C).
3.2. Protection against development of PD in a cohabitation
challenge model
No  signiﬁcant mortality was obtained in the cohabitation model
and efﬁcacy was therefore evaluated by quantiﬁcation and preva-
lence of infectious virus particles in serum, viral RNA in heart tissue
and histological lesions in heart, pancreas and skeletal muscle.
Accumulated prevalences of infectious virus in sera sampled
throughout the experiment were determined in groups vaccinated
with ALV405-based vaccine, commercial SAV vaccine, Placebo
Adjuvant and Placebo PBS to be 2%, 23%, 35% and 39%, respectively.
The qualitative assessment of histological changes demonstrated
full development of PD in all groups except for the groups vacci-
nated with the ALV405-based vaccine. The accumulated prevalence
of ﬁsh carrying viral RNA was  higher than 90% in all groups except
for those vaccinated with the ALV405-based vaccine (Fig. 2A). Total
prevalences of pancreatic lesions that accumulated throughout the
study in the PBS and Placebo Adjuvant groups were 91.5% and 90%,
respectively. In the groups vaccinated with the ALV405-based vac-
cine and the commercial SAV vaccine, the prevalences were 3.2%
and 80% (n = 60 in each group, except the PBS group where n = 59).
Quantitative differences between the ALV405 vaccinated ﬁsh
and the other groups were found to be signiﬁcant (One-way ANOVA
with Bonferroni’s multiple comparison test) both when comparing
levels of viral RNA (Fig. 2B) and histological scores in heart tissues,
pancreatic tissues and skeletal muscle (Fig. 3A–D). No signiﬁcant
differences were found when comparing the three other groups.
3.3.  The ALV405-based vaccine reduces SAV-induced mortality in
a  ﬁeld outbreak
The  efﬁcacy of the ALV405-based vaccine was  tested under ﬁeld
conditions at a commercial farm. Fish had been vaccinated with
either the ALV405 vaccine or the commercial SAV vaccine, tagged
and kept in the same netpen to avoid cage-effects. Under these con-
ditions, a PD outbreak was ofﬁcially diagnosed by histopathological
and PCR analyses. The ALV405-based vaccine reduced mortality sig-
niﬁcantly (p < 0.0001, Chi-square test) compared to the commercial
SAV vaccine, from 8.4% to 5.6% in cage 1 (Fig. 4A) and 19.2% to 8.2%
in cage 2 (Fig. 4B).
3.4.  The ALV405-based vaccine is safe
Local reactions of the ALV405-based vaccine were evaluated
six and twelve weeks after vaccination. The vaccine induced less
adhesions (Fig. 5A and B) and melanization (not shown) of the
viscera than the commercially available vaccine ALPHA JECT®6-2
both when injected alone, and when injected together with the
six-component vaccine ALPHA JECT micro®6.
M. Karlsen et al. / Vaccine 30 (2012) 5688– 5694 5691
Table  1
Efﬁcacy of a 7-component vaccine is dose-dependent. A 7-component test vaccine was made with various amounts of ALV405-antigen in addition to antigen from six other
ﬁsh  pathogens. The relative amount of ALV405-antigen is indicated. Efﬁcacy was  measured by RPS compared to ﬁsh injected with PBS.
Vaccine Fish per tank (n) Relative amount of ALV405 antigen Fish identiﬁcationa RPS tank1 RPS tank 2
PBS 40 0 None NA NA
ALPHA  JECT micro® 6 40 0 AF 35 63
6-components + 1× ALV405 40 1 LM + AF 64 66
6-components + 50× ALV405 40 50 RM + AF 97 92
6-components + 100× ALV405 40 100 LM 89 96
 adipo
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a6-components + 200× ALV405 40 200 
a Fish were tagged by shortening of right maxillae (RM), left maxillae (LM) or the
.5. Protection is dose-dependent and reproducible in a
even-component vaccine formulation
The ALV405 antigen was formulated with four different doses
nto a polyvalent vaccine containing six components from heterol-
gous ﬁsh pathogens. Vaccination of ﬁsh in a laboratory trial with
hese polyvalent vaccines demonstrated an RPS of 97 and 96 in
he parallel tanks at the highest dose (Table 1). When the dose
as reduced 200-fold, the RPS was 64 and 66, demonstrating a
ose-response effect.
.  DiscussionThis study is the ﬁrst description of the performance of a
AV vaccine under laboratory and ﬁeld conditions. Most vaccines
gainst bacterial ﬁsh diseases are based on inactivated bacteria, and
ig. 1. Protection against SAV induced mortality of different vaccines in an i.p. challenge m
urves for both tanks are shown. (B) Normalized expression of viral RNA in heart of surviv
resentation). Fewer ﬁsh were sampled in the PBS group due to few surviving ﬁsh. (C) Qu
nd  skeletal muscle in the same ﬁsh as those presented in (B). ALV405 = ALV405-based vaRM 97 96
se ﬁn (AF).
are generally accepted to induce strong immunity [24]. Vaccines for
ﬁnﬁsh based on inactivated viruses have also been developed, but
their protection is often limited to the reduction of disease sever-
ity, more than a complete protection against disease [25]. Previous
attempts to immunize ﬁsh with inactivated SAV have indicated
that it is possible to obtain some protection in laboratory trials
[14,17,16]. Here we have demonstrated that an inactivated vac-
cine that is based on the Norwegian SAV3 strain ALV405, has a
safety proﬁle equal to or better than existing commercial vaccines,
and can provide a highly efﬁcient protection against infection with
SAV and subsequent development of PD. We  also demonstrated the
attractive possibility of including the ALV405 antigen in a seven-
component vaccine.
Efﬁcacy  of the vaccine was tested in three fundamentally dif-
ferent challenge models in order to obtain a realistic picture of its
performance. The monovalent ALV405-based vaccine induced close
odel. (A) The experiment was run in two parallel tanks and accumulated mortality
ors sampled four weeks p.i. from both parallel tanks (data combined for the sake of
antitative histological assessment of heart (atrium, ventricle and epicard), pancreas
ccine, Comm.  = commercial vaccine, Adj. = placebo adjuvant, PBS = placebo PBS.
5692 M.  Karlsen et al. / Vaccine 30 (2012) 5688– 5694
Fig. 2. Prevalence and quantiﬁcation of viral RNA in hearts of ﬁsh challenged by cohabitation. (A) The prevalence of ﬁsh with detectable levels of viral RNA in heart tissues,
as  measured by Real-Time RT PCR. (B) Log2 transformed normalized expression of viral RNA in hearts of all sampled individuals. Duplicate tanks were used with similar
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pesults. Results from both tanks are combined for the sake of presentation (n = 20 p
dj.  = placebo adjuvant, PBS = placebo PBS.
o complete protection against replication, histopathology and
ortality in both i.p. and cohabitation models, and ﬁsh were signif-
cantly protected against mortality in a ﬁeld trial under industrial
onditions. Results from a second farm where the ALV405-based
accine has been used are in concordance with those shown in
he present work. We  have however observed that vaccinated
sh surviving a ﬁeld outbreak, show histological signs of PD. A
ikely explanation for a potentially reduced performance in the
ig. 3. Quantiﬁcation of tissue lesions in vaccinated ﬁsh challenged by cohabitation. Fish
lacebo  adjuvant vaccine (C) or PBS (D), and the histological lesions that developed 3–5 wup per time-point). ALV405 = ALV405-based vaccine, Comm. = commercial vaccine,
ﬁeld  compared to what is seen in laboratory trials is the constant
presence of various heterologous pathogens in ﬁeld populations.
In the farm included in this study, as well as in the second farm
described above, at least two other pathogens, sea lice (Lepeoph-
theirus salmonis) and the microsporidian Paranucleospora theridion,
were present in the ﬁsh population. Both parasites are common in
farmed populations of Atlantic salmon in Norway, and believed to
have immune-suppressive effect on the host [26,27].
 were vaccinated with the ALV405-based vaccine (A), a commercial vaccine (B), a
eeks post challenge are shown (n = 20 per time-point, per group).
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Fig. 4. Efﬁcacy of the ALV405-based vaccine under industrial ﬁeld conditions. A commercial ﬁsh population was vaccinated in the period December 2010–February 2011
with either the ALV405-based vaccine or a commercial SAV vaccine, and kept as a mixed population in two  cages (A and B). Fish vaccinated with the ALV405-based vaccine
w reak o
D  accor
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6ere tagged by adipose ﬁn removal for identiﬁcation. The farm experienced an outb
ifferences in accumulated mortality among test groups are signiﬁcant (p < 0.0001)
Although the efﬁcacy of the ALV405-based vaccine was simi-
ar in both laboratory models used, the efﬁcacy of the commercial
accine and the placebo adjuvant vaccine was not. Both vaccines
ppeared to provide a signiﬁcant effect in the i.p. challenge model
hat could not be detected when ﬁsh were challenged through the
ssumed natural challenge route, i.e. in the cohabitation model.
he conﬂicting results observed for the two laboratory models are
ikely to result from the fact that the challenge virus is injected
n the same spatial area as the vaccine in the i.p. model. Thus the
hallenge virus is released into an area where there is a chronic
nd active inﬂammatory response [28]. These results highlight the
ig. 5. Safety proﬁle of the ALV405-based vaccine compared to commercial vaccines. 
odiﬁed Speilberg’s scale 6 (A) and 12 weeks (B) post vaccination in three different regio
, ALV405 = monovalent ALV405-based vaccine.f PD, and the accumulated mortalities after sea transfer from both cages are shown.
ding to a Chi-square test.
importance of studying vaccines under various conditions to obtain
a more complete understanding of their performance.
The present vaccine situation in the European salmonid farming
industry is suboptimal. Despite vaccination of the ﬁsh population
in exposed areas, the SAV epizootics remain as a major loss-
contributing factor to the industry [4]. Moreover, the available
SAV-vaccine must be given as a separate injection from a multi-
component vaccine, with at least 230 day degrees separating the
injections. This is an additional stressor for the ﬁsh and costly to the
farmer. The high level of protection combined with the possibility
to include the ALV405 antigen in a multi-component vaccine could
Local reactions deﬁned by adhesions of the viscera, were scored according to a
ns of the peritoneal cavity. AJ6-2 = ALPHA JECT® 6-2, Micro6 = ALPHA JECT micro®
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herefore represent a signiﬁcant improvement for both ﬁsh health
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ppendix  A. Supplementary data
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/
.vaccine.2012.05.069.
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